Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome)
- PMID: 21037085
- PMCID: PMC3035077
- DOI: 10.1182/blood-2010-05-287607
Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome)
Abstract
Mucopolysaccharidosis type I (MPS IH; Hurler syndrome) is a congenital deficiency of α-L-iduronidase, leading to lysosomal storage of glycosaminoglycans that is ultimately fatal following an insidious onset after birth. Hematopoietic cell transplantation (HCT) is a life-saving measure in MPS IH. However, because a suitable hematopoietic donor is not found for everyone, because HCT is associated with significant morbidity and mortality, and because there is no known benefit of immune reaction between the host and the donor cells in MPS IH, gene-corrected autologous stem cells may be the ideal graft for HCT. Thus, we generated induced pluripotent stem cells from 2 patients with MPS IH (MPS-iPS cells). We found that α-L-iduronidase was not required for stem cell renewal, and that MPS-iPS cells showed lysosomal storage characteristic of MPS IH and could be differentiated to both hematopoietic and nonhematopoietic cells. The specific epigenetic profile associated with de-differentiation of MPS IH fibroblasts into MPS-iPS cells was maintained when MPS-iPS cells are gene-corrected with virally delivered α-L-iduronidase. These data underscore the potential of MPS-iPS cells to generate autologous hematopoietic grafts devoid of immunologic complications of allogeneic transplantation, as well as generating nonhematopoietic cells with the potential to treat anatomical sites not fully corrected with HCT.
Figures





Similar articles
-
Efficient hematopoietic redifferentiation of induced pluripotent stem cells derived from primitive murine bone marrow cells.Stem Cells Dev. 2012 Mar 20;21(5):689-701. doi: 10.1089/scd.2011.0010. Epub 2011 Aug 24. Stem Cells Dev. 2012. PMID: 21732815
-
The timing of retroviral silencing correlates with the quality of induced pluripotent stem cell lines.Biochim Biophys Acta. 2011 Feb;1810(2):226-35. doi: 10.1016/j.bbagen.2010.10.004. Epub 2010 Oct 20. Biochim Biophys Acta. 2011. PMID: 20965232
-
Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients.Mol Genet Metab. 2013 Aug;109(4):377-81. doi: 10.1016/j.ymgme.2013.05.016. Epub 2013 Jun 4. Mol Genet Metab. 2013. PMID: 23786846
-
Generation of clinically relevant "induced pluripotent stem" (iPS) cells.J Stem Cells. 2011;6(3):109-27. J Stem Cells. 2011. PMID: 23264997 Review.
-
[Induction and characterization of induced pluripotent stem (iPS) cells: a review].Sheng Wu Gong Cheng Xue Bao. 2010 Apr;26(4):421-30. Sheng Wu Gong Cheng Xue Bao. 2010. PMID: 20575428 Review. Chinese.
Cited by
-
Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseases.Stem Cell Res Ther. 2012 Aug 28;3(4):34. doi: 10.1186/scrt125. Stem Cell Res Ther. 2012. PMID: 22925465 Free PMC article. Review.
-
Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa.Pediatr Res. 2018 Jan;83(1-2):318-324. doi: 10.1038/pr.2017.244. Epub 2017 Nov 1. Pediatr Res. 2018. PMID: 29593249 Review.
-
New lessons learned from disease modeling with induced pluripotent stem cells.Curr Opin Genet Dev. 2012 Oct;22(5):500-8. doi: 10.1016/j.gde.2012.05.005. Epub 2012 Jun 28. Curr Opin Genet Dev. 2012. PMID: 22749051 Free PMC article. Review.
-
Niemann-Pick Disease Type C: Induced Pluripotent Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy.J Biomol Screen. 2014 Sep;19(8):1164-73. doi: 10.1177/1087057114537378. Epub 2014 Jun 6. J Biomol Screen. 2014. PMID: 24907126 Free PMC article.
-
Number of polyploid giant cancer cells and expression of EZH2 are associated with VM formation and tumor grade in human ovarian tumor.Biomed Res Int. 2014;2014:903542. doi: 10.1155/2014/903542. Epub 2014 Jun 15. Biomed Res Int. 2014. PMID: 25025074 Free PMC article.
References
-
- Fratantoni JC, Hall CW, Neufeld EF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science. 1968;162(853):570–572. - PubMed
-
- Hobbs JR, Hugh-Jones K, Barrett AJ, et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet. 1981;2(8249):709–712. - PubMed
-
- Orchard PJ, Blazar BR, Wagner J, Charnas L, Krivit W, Tolar J. Hematopoietic cell therapy for metabolic disease. J Pediatr. 2007;151(4):340–346. - PubMed
-
- Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344(3):182–188. - PubMed
-
- Krivit W, Sung JH, Shapiro EG, Lockman LA. Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant. 1995;4(4):385–392. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials